|Author: Junping Wu, Cherie S. Tan, Hongzhi Yu, Youwei Wang, Yutao Tian, Wenwei Shao, Yifei Zhang, Kuo Zhang, Hongxia Shao, Guangjian Ni, Jun Shen, Antonio Carlo Galoforo, Qi Wu, Dong Ming.|
Scheme of Ozonated Autohemotherapy for COVID-19 Patients
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA betacoronavirus,1 that has spread globally since December 2019. As of July 22, 2020, more than 14,000,000 confirmed cases and 607,781 deaths from COVID-19 have been reported to the World Health Organization from 216 areas and territories.2 Patients with more prominent laboratory abnormalities may develop acute respiratory distress syndrome (ARDS), which potentially leads to multiple organ failure and death.1,3 However, at present, there are no regulatory approved antiviral medicines, vaccines, or specific clinical treatments for COVID-19.
Cite this article
Wu, J., Tan, C.S., Yu, H., Wang, Y., Tian, Y., Shao, W., Zhang, Y., Zhang, K., Shao, H., Ni, G., Shen, J., Galoforo, A.C., Wu, Q. and Ming, D. Recovery of Four COVID-19 Patients via Ozonated Autohemotherapy. The Innovation 1 (3), 100060 (2020). doi: 10.1016/j.xinn.2020.100060